Ocular Therapeutix Inc

Ocular Therapeutix Inc. a biopharmaceutical company focuses on the formulation development and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets ReSure Sealant an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery as well as allergic conjunctivitis. It is also developing OTX-TKI an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC a travoprost intracameral implant which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED a dexamethasone intracanalicular insert which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. Ocular Therapeutix Inc. has a strategic collaboration with Regeneron Pharmaceuticals Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD). The company was incorporated in 2006 and is headquartered in Bedford Massachusetts.